Wedbush Has Pessimistic Outlook of argenex Q2 Earnings

argenex SE (NASDAQ:ARGX) – Investment analysts at Wedbush cut their Q2 2025 earnings per share estimates for shares of argenex in a research note issued on Monday, June 16th. Wedbush analyst D. Nierengarten now expects that the company will earn $3.43 per share for the quarter, down from their prior estimate of $4.19. Wedbush currently has a “Outperform” rating and a $715.00 target price on the stock. The consensus estimate for argenex’s current full-year earnings is $3.13 per share. Wedbush also issued estimates for argenex’s Q3 2025 earnings at $4.49 EPS, Q4 2025 earnings at $5.43 EPS, Q1 2026 earnings at $6.58 EPS, Q2 2026 earnings at $7.71 EPS, Q3 2026 earnings at $7.21 EPS, FY2026 earnings at $29.33 EPS, FY2027 earnings at $38.72 EPS and FY2028 earnings at $53.89 EPS.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, May 8th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.32 by $0.26. argenex had a return on equity of 16.15% and a net margin of 40.20%. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $748.34 million.

ARGX has been the topic of several other research reports. Robert W. Baird upgraded shares of argenex from a “neutral” rating to an “outperform” rating and set a $680.00 price target on the stock in a research report on Tuesday, May 13th. Citigroup restated a “buy” rating on shares of argenex in a research note on Wednesday, May 21st. HC Wainwright reaffirmed a “buy” rating and issued a $720.00 target price on shares of argenex in a report on Tuesday, June 10th. Oppenheimer boosted their price target on argenex from $704.00 to $708.00 and gave the stock an “outperform” rating in a report on Friday, May 9th. Finally, Sanford C. Bernstein upgraded argenex from a “market perform” rating to an “outperform” rating in a research report on Monday, March 17th. One analyst has rated the stock with a hold rating, nineteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, argenex currently has a consensus rating of “Buy” and an average price target of $709.18.

argenex Stock Down 0.5%

ARGX stock opened at $537.92 on Wednesday. The company’s 50-day moving average price is $586.57 and its two-hundred day moving average price is $610.16. The firm has a market cap of $32.85 billion, a P/E ratio of 33.18, a P/E/G ratio of 0.98 and a beta of 0.39. argenex has a 12 month low of $379.39 and a 12 month high of $678.21.

Institutional Investors Weigh In On argenex

A number of institutional investors have recently added to or reduced their stakes in ARGX. FMR LLC lifted its holdings in shares of argenex by 17.2% during the fourth quarter. FMR LLC now owns 5,618,222 shares of the company’s stock worth $3,455,207,000 after purchasing an additional 824,750 shares during the period. Millennium Management LLC raised its position in argenex by 316.9% during the 1st quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock worth $158,977,000 after purchasing an additional 204,180 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in argenex during the 4th quarter worth about $91,013,000. GAMMA Investing LLC lifted its holdings in argenex by 53,684.9% during the 1st quarter. GAMMA Investing LLC now owns 135,538 shares of the company’s stock worth $802,200,000 after buying an additional 135,286 shares during the period. Finally, Marshall Wace LLP grew its position in shares of argenex by 184.7% in the 4th quarter. Marshall Wace LLP now owns 191,553 shares of the company’s stock valued at $117,805,000 after buying an additional 124,271 shares during the last quarter. 60.32% of the stock is owned by institutional investors.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.